News Hub | News Direct

With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO

Sharps Technology Inc.

By David Willey, Benzinga Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in manufacturing and marketing, and is rolling out the first of its innovative syringe products. The syringe market is worth over $6 billion. The pandemic raised public awareness about the importance of a strong and steady syringe supply. Now, pharmaceutical and manufacturing companies are turning to next-generation solutions like prefillable syringes, which deliver medicine utilizing enhanced features and benefits that will support a lower cost of total ownership (TCO) for healthcare companies. Sharps Technology is a medical device and drug delivery company focusing on specialized and prefillable syringes. Public since April 2022, Sharps is looking to fulfill demand in the market and modernize syringe offerings through its line of polymer prefillable and ultra-low waste safety syringes. A year on from its IPO, Sharps can reflect on a series of robust company successes and exciting developments. IPO, Manufacturing Successes, And A Key Partnership IPO. Sharps launched its IPO of common stock in April 2022. The company issued 3.75 million units of public stock at $4.25 per unit, with proceeds from the IPO coming to around $16 million. Hungary Facility. The company acquired a manufacturing facility in Hungary, which allows Sharps to manufacture its smart safety syringes with a production capacity of 50 million units. It shipped its first set of containers of smart safety syringes early this year, bringing them from its Hungarian facility to U.S. partner, Nephron Pharmaceuticals headquartered in South Carolina. Sharps CEO, Robert Hayes, commented on the shipment, “With the first shipments of Securegard underway to Nephron, we mark the beginning of commercial operations for Sharps. We are committed to executing on our manufacturing and distribution plan, and through this shipment the Company will transition to revenue in the first half of 2023.” Nephron Collaboration. Sharps entered a major partnership with leading drug and manufacturing services company Nephron Pharmaceuticals Corporation. The collaboration will allow Sharps access to manufacturing and marketing solutions at Nephron, and will include full access to Nephron's analytical labs for continued product development. The partnership allows Sharps to accelerate the development and manufacturing of its product line of prefillable syringe systems. Robert Hayes, Sharps Chief Executive Officer, recently stated: “Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opportunity to advance our product and manufacturing strategy to include high-value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the U.S. that provide specialized solutions for customers that need options for their drug-filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market.” Other companies working in the syringe market are Becton Dickson and Co. (NYSE: BDX), Cardinal Health (NYSE: CAH), Novo Nordisk N/S (NYSE: NVO), and Terumo Corporation (OTC: TRUMY). This article was originally published on Benzinga here. Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Adam Holdsworth- TraDigital IR adam@tradigitalir.com Company Website http://sharpstechnology.com/

February 15, 2023 09:55 AM Eastern Standard Time

How To Improve Mental Well-Being — TruBrain’s Non-Pharmaceutical Solutions Could Help Fight Anxiety For Stress-Free Living

TruBrain

By David Willey, Benzinga You can invest in TruBrain and be a part of their growth story! Click here to learn more. Stress is so ubiquitous today that it has been called “a national mental health crisis.” Being bombarded with rising food prices, novel virus variants, layoffs and inflation means it's important to get your mind right and your anxiety managed so you can have a successful 2023. The Los Angeles-based cognitive health company TruBrain might have the solution you need for achieving that calm and anxiety-free mind. Anxiety is overwhelming for Millenials and Gen Z, with over 50% of those under 35 reporting dealing with crippling stress levels daily. The US represents the largest segment of the global anxiety and depression market, and with the worrying risks of side effects and addiction associated with anxiety medication like benzodiazepine, there’s growing interest in a non-pharmaceutical solution to stress. TruBrain is a natural cognitive enhancing nutrition company, with a variety of products that promote clarity of thought, sharp memory, and peaceful sleep. The company is riding the wave of a $3.3 billion nootropic market growing in popularity by developing drinks and other products which promote clear and calm concentration, and it’s excited to help people maximize their brain potential for healthier living. TruBrain’s Products For Mental Well-Being Set to be a leader of nootropic drinks and with 5 stars from over 571 reviews, TruBrain’s most popular product is its personalized drinks package, whose extensive range means each person can personalize their drinks to treat their brain best. Its science-backed drinkable products include key nootropics and minerals to reduce stress and unlock focus. The drinks, which were developed by a team of University of California Los Angeles-trained (UCLA) neuroscientists, have been shown by EEG brainwave analyses and third party clinicals studies to promote healthy brain functions like improved memory, verbal fluency, and alpha brain activity. TruBrain was also recently rated the best nootropics for dealing with stress and anxiety. The cognitive healthcare company is also excited about its upcoming wearable tech which tackles anxiety by supporting natural brain activity. TruBrain’s Smart Wearable uses Food and Drug Administration (FDA)-cleared tech to send safe, micro electric currents to increase blood flow to key parts of the brain, giving users a non-pharmaceutical solution to lessen anxiety and promote calm. Backed by thousands of scientific studies and decades of research, the tech used by TruBrain provides neurostimulation that can produce results in just 30 minutes, activating neurons and nudging neurotransmitter activity for a clear and stress-free mind. “Our mission is to empower people to do their best thinking,” said CEO of TruBrain Chris Thompson. “The problems we’re trying to solve are stress and anxiety. That will clear the runway for you to focus more, relax and get better sleep.” TruBrain has made over $19 million in lifetime sales and has been profitable since 2019. Supported by 2000+ grassroots investors and with over $4 million already raised, the company has built a robust distribution network with the mission to become the leading cognitive healthcare brand. TruBrain’s comparables in the space are successful companies like Hims (NYSE: HIMS), RXBar, Amplify Snack Brands, and others. TruBrain is currently raising funds via a new round of investing, with investors getting free products to sample – will it become the next healthcare success story? Want to find out how to invest in TruBrain? Click here. Want to learn more about TruBrain? Visit its website here. This article was originally published on Benzinga here. TruBrain is a profitable brand in high-performance cognitive nutrition with over $18 million in lifetime sales. We deliver patent-pending brain food designed by neuroscientists to enhance your memory, focus, sleep, and more. Our personalized formulas will empower you to be the best version of your unique self. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details TruBrain Investor Relations invest@trubrainstock.com Company Website https://www.trubrain.com/

February 15, 2023 09:25 AM Eastern Standard Time

Applied UV’s (NASDAQ: AUVI) Subsidiary Embarks On Research Partnership With Johnson Controls And Ushio America To Study The Efficacy And Safety Of Filtered Far UV-C Disinfection Technology

Applied UV, Inc.

By Ernest Dela Aglanu, Benzinga Applied UV Inc. (NASDAQ: AUVI) is leading a new wave of innovation in the ultraviolet (UV) disinfection equipment industry. This is good, considering the critical role UV plays in keeping indoor spaces and medical facilities free of pathogens. UV disinfection has been a proven technology for the disinfection of pathogens on surfaces and in air and water for several decades. A particular spectrum of UV radiation between 200 and 280 nm – the UVC spectrum – has been employed extensively as the germicidal range of UV radiation. Global health crises, like the COVID-19 pandemic, highlight the scientific and engineering potential of applying UV disinfection technologies for biocontaminated air and surfaces as the major media for disease transmission. More businesses and institutions, such as healthcare facilities, shopping malls and airports, are increasingly adopting UV devices for disinfecting frequently touched surfaces and circulating air streams. The increasing adoption of UV disinfection is translating into a positive growth outlook for the market, something investors are always looking out for. Grand View Research projects the global disinfection equipment market will reach $6.17 billion by 2030, expanding at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. So, for a player like Applied UV, which develops and acquires proprietary infection prevention and control technology in the healthcare, commercial and public venue, food processing and storage, cannabis, and education markets, the advancing growth of the market presents opportunities. The company has two wholly owned subsidiaries — SteriLumen Inc. and Munn Works LLC. SteriLumen owns and markets a portfolio of products with advanced pathogen elimination technology, branded Airocide® by SteriLumen, Scientific Air™ by SteriLumen, Airoclean™ 420 by SteriLumen, and Lumicide™ by SteriLumen. Research Collaboration To Study The Efficacy And Safety Of Far-UVC Disinfection Technology In a quest to advance and enhance its technology, Applied UV recently announced that its subsidiary, PURO Lighting LLC, a proven innovative UV technology solutions leader, Johnson Controls International PLC. (NYSE: JCI), a leader for smart, healthy, and sustainable buildings, and Ushio America Inc., have announced a research collaboration to study the efficacy and safety of far-UVC disinfection technology. Far-UVC is a narrow band of UVC light centered at 222nm, which is proven to inactivate pathogens at levels that are safe for human exposure and can be used in spaces where people are present. While the efficacy of filtered far UV-C light disinfection is widely known, there is limited research on the ancillary effects that occur from the inactivation of pathogens using far UV-C light. Therefore, the planned study being embarked upon by PURO and Ushio will allow for a better understanding of the possible positive and negative impact the elimination of pathogens has on the surrounding air. “The further validation of the safety and efficacy of filtered far UV-C technology presents tremendous opportunity for PURO to accelerate market adoption by sponsoring this critical research,” Brian Stern, president of PURO, said in a press release. He further noted that the research will help demonstrate the benefits and potential cost savings that continuous disinfection of air and surfaces can bring to workplace settings, including hospitals, schools, government buildings, commercial offices and other shared indoor spaces. Tyler Smith, vice president of Healthy Buildings, Johnson Controls, on his part explained that “Better indoor air quality (IAQ) is increasingly important to our customers and our employees, and it’s critical we evaluate all of the factors that go into the IAQ equation.” “We are intrigued and excited by the early promise of far UV-C as a supplement to our leading IAQ solution portfolio. By testing PURO and Ushio’s market-leading far UV-C technologies, we will be able to provide customers with additional, proven, safe and effective solutions to ensure that the air and surfaces in indoor spaces are healthier and more sustainable,” he added. For Ushio, the research collaboration presents an opportunity for the company to build on its existing research and findings to further prove the efficacy and safety of Care222 filtered far UV-C technology. “The capability to provide continuous UV disinfection of air and surfaces in occupied spaces has become the industry standard. This research will help provide the confidence to customers that the technology is not only effective but safe,” Shinji Kameda, COO of Ushio, said. The research agreement, which includes technologies and products from PURO and Ushio, will focus on testing regulatory-approved filtered far UV-C lighting technologies. The research will be conducted by leading U.S.-based universities and certified laboratories over the next six to eight months. The findings from the results will be provided as they become available. A recently released white paper from Johnson Controls highlights that better indoor air quality can conservatively lead to a $750 to $800 return per employee per year by reducing absenteeism from health issues and the reduction in productivity due to poor air quality. This article was originally published on Benzinga here. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

February 15, 2023 09:00 AM Eastern Standard Time

Introducing MicroGuard™ by Microban®: antimicrobial technology for PU, EVA and PVC products

Microban International

Microban International is pleased to expand its portfolio of antimicrobial technologies with the introduction of MicroGuard ™, a series of antifungal additives for PVC, PU, and EVA applications including foam. MicroGuard technology provides high antifungal efficacy and 24/7 built-in protection, preventing microbial degradation to extend the useful product lifetime. This innovative solution from the global leader in antimicrobials is part of Microban’s commitment to bringing novel technologies to market with more friendly toxicity profiles than currently available agents. MicroGuard has been developed as a non-leaching antifungal agent comprised of active ingredients that are free from metals, offering an alternative to arsenic-based OBPA – a common antifungal additive – that is causing regulatory concerns due to its ability to contaminate water sources and harm aquatic life. Michael Ruby, President at Microban International, commented: “We are pleased to introduce MicroGuard, a metal-free technology designed to combat fungal growth on PVC products, as well as on PU and EVA foams. MicroGuard’s more favourable toxicity profile is ahead of the curve in terms of shifts in the regulatory landscape concerning built-in antifungals for these goods, offering manufacturers a highly effective built-in solution to increase product durability.” MicroGuard can be seamlessly integrated into PVC, PU and EVA products at the point of manufacture, and has been designed for use in a broad range of applications. The technology can be incorporated into outdoor PVC products – roofing membranes, tarpaulin, awnings and decking – and used to treat goods manufactured from PU and EVA foams, including shoe soles, furniture cushions and mattresses. Dr Souvik Nandi, Vice President of Technology and Innovations at Microban International, added: “MicroGuard has been carefully developed using our extensive in-house expertise to meet the diverse needs of PU, EVA and PVC manufacturers. Available in both pellet and liquid formulations, MicroGuard has global registration to offer manufacturers confidence in treating their polymer products.” The technology is available to brands and manufacturers globally, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/microguard and get in touch with a representative today. Microban will be exhibiting MicroGuard at the AMI’s fifth PVC Formulation from February 21-22, 2023, where Mai Ha, Senior Product Development Engineer at Microban International, will be discussing how the next generation of PVC antimicrobials is creating a cleaner future. Microban will also be showcasing MicroGuard at booth 8725 in exhibit halls A-E at the International Roofing Expo (IRE) March 7 - 9, 2023. About Microban International Part of Barr Brands International (BBI), Microban International is home to the most trusted and well-known global brands in the antimicrobial, odour control, and sanitisation / disinfection markets – Microban® and Ultra-Fresh®. Our organisation has experienced over 100 collective years of growth and has revolutionised the industry. As the global leader, our proactive systems keep products cleaner, and control odours better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products around the world. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina with operations in North America, Europe, and Asia Pacific. For more information, please visit www.microban.com. © 2023 kdm communications limited Contact Details Audrey Jestin at kdm communications limited, St Neots, UK Fax: +44 (0) 1480 477833 +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

February 15, 2023 09:00 AM Eastern Standard Time

Image

News Release

6 Best Coursework Writing Services For Academic Excellence 📚

Halvorson Media Group

If you're looking for the best coursework writing service, then you should read this article. Find out the best coursework writing services that will help you get the grades you need. If you're like most students, you probably feel the pressure of coursework piling up. The good news is that there are 6 best coursework writing services that will take the burden off your shoulders: 1. PaperHelp - Superior overall 🥇 2. CheapPaper - Excellent reputation 💯 3. Evolution - Ideal for a ton of freebies 💡 4. 99papers - Fast and cheap work results; 5. SpeedyPaper - Best for large-scale tasks; 6. Essaybox - High-quality writing solutions. How to choose the best coursework writing service To get the most out of your coursework writing service, it is essential to be aware of the many factors that can influence your choice. Customer reviews, pricing policies, turnaround times, and a proven track record of delivering top-notch content should all be considered. Also, look for a professional team of writers and experienced editors who can guarantee high-quality results at every stage of the process. Why choose these companies We have selected these 6 best professional writing companies because they have a team of professional writers who are experienced in various disciplines and can provide coursework assistance. Their writers also have extensive research skills and take the time to make sure they understand all your instructions. They offer a range of services tailored to the needs of the project at hand, so you can be sure that your coursework will be done correctly and efficiently. Overall, these professional writing services provide reliable coursework for all types of clients and can ensure the timely completion of complex projects. Professional coursework writing services Reliable and trustworthy coursework writing services help students with their coursework quickly and easily. These professional online coursework helpers can meet tight deadlines and leave no room for late submissions or rushed work of low quality. With their expert writers, these coursework essay writing service providers understand their customers’ needs of their clients and deliver high-quality papers. 1. PaperHelp - Superior overall 🥇 Paperhelp is the perfect academic essay writing service when it comes to ordering coursework. It is easy to buy coursework from Paperhelp because they offer a wide range of academic support in various subjects to complete your assignment satisfactorily. The company has an experienced team of professional writers who make sure that every academic paper you order is perfectly written. Customer service is always available. All in all, Paperhelp is the perfect partner if you are looking for reliable and affordable academic writing services that will help you pass any exam or term paper. Pros: Low price: Paperhelp writing service offers cheap coursework help for students that costs about $10. Additional services: Paperhelp’s coursework writing service offers convenient features like secure payment methods, customer service support, and even delivery insurance for the timely completion of assignments. Useful mobile app: This software has a user-friendly design that makes it easy to submit new orders and keep track of ongoing tasks. Cons: There have been cases where users have been disappointed due to incompletely delivered orders and factual inaccuracies. Sluggish, ESL support staff: customer service staff are not native English speakers and are too busy to respond within 15 minutes. 2. CheapPaper - Excellent reputation 💯 If you are looking for a reliable and affordable writing service, check out CheapPaper coursework writing service. Customers can take advantage of their extensive custom essay and coursework writing services at extremely low prices. Their writers are highly qualified and can deliver high-quality material to meet any deadline. In addition, they also provide a plagiarism checker to ensure that all written materials are as original and authentic as possible. If you are buying coursework from CheapPaper, you can be sure that your work is in safe hands - they guarantee full customer satisfaction with every order. Pros: Numerous options: Work delivered on time and customized to your specifications. Professional coursework writers: CheapPaper has expert writers, able to handle any coursework. Speed of work: Commitment to delivering quality content on tight schedules makes them perfect for any type of academic paper, from simple book reports to detailed dissertations. Excellent feedback: The company has excellent reviews from students who have used its services. Cons: There is no chat representative: It is not possible to consult directly on-site for a short time. Problems with the coursework website: There are grammatical, spelling, and syntactical errors throughout the website. 3. Evolution - Ideal for a ton of freebies 💡 If you are looking for an experienced coursework writing service, you can rely on Evolution Writing Service. Professional coursework writers are experts in the industry and have been helping students with their coursework for years. The company specializes in custom coursework services and can help you with topics such as research papers, term papers, dissertations, book reviews, and much more. The teams are experts in a variety of subjects, from literature to biology. Pros: Service works with many topics: The writing service can help identify sources or create a hypothesis and methodology when dealing with complex topics. Payment options: PayPal and all major credit cards are accepted by EvolutionWriters. You can feel completely safe giving your financial information to EvolutionWriters, as the company uses a reputable third-party payment processor. As far as we know, the company has not experienced any system breach. Low price: compared to their competitors, the cost is quite affordable. They charge about $10 per page for an undergraduate paper, $16 for a graduate paper, $19 for a professional paper, and $41 for an admission paper. Cons: Unsatisfied comments: Unfortunately, students have sometimes expressed dissatisfaction with the ordered work due to missed deadlines or errors in the text. 4. 99papers - Fast and cheap work results For students looking for the most reliable and best coursework writing service, 99Papers is a perfect choice. With their online coursework help, customers can find professional and experienced coursework writers who know how to deliver quality work for any assignment. Specific requirements are followed meticulously and included in the assignment, so you know that all requirements have been met. Customers' needs of the clients come first, which makes it easy to find a suitable coursework writer to fit your project. All you need to do is provide your instructions and they will take care of the rest while ensuring customer satisfaction throughout the process. The trustworthy customer service answers all questions and offers helpful advice when you need it most. Pros: Professional coursework writers: 99papers has experienced writers. Delivery: Flexible delivery times can be an ideal solution for busy students who need reliable coursework support. Promo code for 10% off your first purchase at 99papers.com: get a 99papers coupon as a new customer to lower the price. There is a rewards program that will give you back 15% of the money you spend on incentives. Low price: coursework help service charges a low price of $9 for its work. Cons: Some report that their editing services are not always up to par, which could be concerning for those seeking professional help with the structure or grammar of their essays. Inadequate customer service: support staff took a long time to respond to messages and sometimes gave pre-written answers that didn't address the specific request. 5. SpeedyPaper - Best for large-scale tasks If you are looking for an efficient writer or a last-minute writing service, Speedypaper is the perfect website for you. With its team of highly professional and experienced writers, Speedypaper guarantees top-notch results within tight deadlines - allowing you to submit excellent coursework just in time. At the same time, Speedypaper offers competitive prices and discounts of up to 25%, which makes their services even more attractive. In addition, every order includes a free plagiarism report, which guarantees that all papers are 100% authentic. Pros: Excellent coursework writers: Professional writers specialize in a wide range of writing genres, from academic essays to resumes, business plans, and more. Offers several advantages: Fast turnaround times, secure payments, and expert advice make them the perfect partner for busy professionals and businesses seeking professional writing services. Great online support: The support staff was always available and answered questions quickly. Reviews: Professional coursework writing service has really great feedback. Cons: Limited customer service accessibility, poor communication with clients' accounts, and occasional misspellings or errors in their online deliveries. 6. Essaybox - High-quality writing solutions Essaybox offers comprehensive academic writing services, from essays to dissertations. When you choose this coursework help platform, you get high-quality help for all types of academic papers, including research papers, creative writing, project reports, and case studies. EssayBox writing service offers comprehensive solutions for every writing need. It proactively supports its clients with helpful tips and guides for better essay and dissertation writing. The main goal is to deliver quality projects on time. From ensuring secure payments to round-the-clock customer service, EssayBox writing service shows transparency in its operations, making it a trusted brand when it comes to writing services. Pros: Expeditious paper completion: The writing service is designed in such a way that you can finish your project quickly and with high quality. Many topics and difficulty levels are offered: Whether it is about current affairs, social issues, art, culture, science, or technology, you can buy cheap coursework for any purpose. The coursework website is clear and easy to navigate: From the first page of the EssayBox website, you can quickly find the information you need. Cons: You can get a plagiarism report if you pay extra: To get a plagiarism report, you have to pay an extra $9.99. Lack of transparency regarding the writers' qualifications: On the website in the tab of the profiles of the authors of the work there is very little information about the professionals who do their work. FAQ Section Why should you use a coursework writing service? Coursework writing service provides professional writers who understand the requirements of your courses and ensure that your assignment is both accurate and successful. Quality writers think critically to find research-backed arguments or solutions to questions or problems in your coursework, saving you time and effort. In addition, professional writers have the necessary skills to logically structure your coursework, check for grammatical and spelling errors, and create unique content within strict deadlines. They can also help you look at a topic from different angles or expand on certain areas as required by your professor. Can students examine the papers' quality before buying writing assistance? Absolutely! As a student, you should always be able to research and get an idea of the quality of an online writing service before using it. Luckily, these 6 best coursework writing services offer potential clients the opportunity to view sample papers to get a better idea of the quality of the company in question. Many also offer the ability to view ratings and reviews from previous clients to get other customers' opinions of the service. Are the top coursework writing services you recommend safe to use? Yes, the best coursework writing services are safe to use. Here are some reasons why: The companies that provide these services are professional and experienced. They know how to handle confidential information and will keep your information secure. These homework help services have a good reputation. They have been in business for many years and have helped thousands of students with their assignments. You can be sure that they will do a great job for you. They offer a money-back guarantee. This means that you can get your money back if you are not satisfied with the work. Overall, using this best coursework writing service is a safe and easy way to get help with your assignments. Do these coursework writing services firms plagiarize? No! Coursework help services from this article will write a unique paper for you. If you use the coursework website we recommend, you'll probably never face any plagiarism problems. Conclusion To find the best coursework writing service, you need to consider a few things, such as the level of experience, affordability, customer reviews, and guarantees. We have compiled a list of the six best coursework writing services that meet these criteria. We hope that this list will help you choose the best coursework writing service. Contact Details Halvorson Media Group Edward +1 929-491-3157 edward@halvorsonmediagroup.com Company Website https://halvorsonmediagroup.com/

February 15, 2023 07:28 AM Eastern Standard Time

Introducing MicroGuard™ by Microban®: antimicrobial technology for PU, EVA and PVC products

Microban International

Microban International is pleased to expand its portfolio of antimicrobial technologies with the introduction of MicroGuard ™, a series of antifungal additives for PVC, PU, and EVA applications including foam. MicroGuard technology provides high antifungal efficacy and 24/7 built-in protection, preventing microbial degradation to extend the useful product lifetime. This innovative solution from the global leader in antimicrobials is part of Microban’s commitment to bringing novel technologies to market with more friendly toxicity profiles than currently available agents. MicroGuard has been developed as a non-leaching antifungal agent comprised of active ingredients that are free from metals, offering an alternative to arsenic-based OBPA – a common antifungal additive – that is causing regulatory concerns due to its ability to contaminate water sources and harm aquatic life. Michael Ruby, President at Microban International, commented: “We are pleased to introduce MicroGuard, a metal-free technology designed to combat fungal growth on PVC products, as well as on PU and EVA foams. MicroGuard’s more favourable toxicity profile is ahead of the curve in terms of shifts in the regulatory landscape concerning built-in antifungals for these goods, offering manufacturers a highly effective built-in solution to increase product durability.” MicroGuard can be seamlessly integrated into PVC, PU and EVA products at the point of manufacture, and has been designed for use in a broad range of applications. The technology can be incorporated into outdoor PVC products – roofing membranes, tarpaulin, awnings and decking – and used to treat goods manufactured from PU and EVA foams, including shoe soles, furniture cushions and mattresses. Dr Souvik Nandi, Vice President of Technology and Innovations at Microban International, added: “MicroGuard has been carefully developed using our extensive in-house expertise to meet the diverse needs of PU, EVA and PVC manufacturers. Available in both pellet and liquid formulations, MicroGuard has global registration to offer manufacturers confidence in treating their polymer products.” The technology is available to brands and manufacturers globally, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/microguard and get in touch with a representative today! Microban will be exhibiting MicroGuard at the AMI’s fifth PVC Formulation from February 21-22, 2023, where Mai Ha, Senior Product Development Engineer at Microban International, will be discussing how the next generation of PVC antimicrobials is creating a cleaner future. Microban will also be showcasing MicroGuard at booth 8725 in exhibit halls A-E at the International Roofing Expo (IRE) March 7 - 9, 2023. About Microban International Part of Barr Brands International (BBI), Microban International is home to the most trusted and well-known global brands in the antimicrobial, odour control, and sanitisation / disinfection markets – Microban® and Ultra-Fresh®. Our organisation has experienced over 100 collective years of growth and has revolutionised the industry. As the global leader, our proactive systems keep products cleaner, and control odours better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products around the world. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina with operations in North America, Europe, and Asia Pacific. For more information, please visit www.microban.com. © 2023 kdm communications limited Contact Details Audrey Jestin at kdm communications limited, St Neots, UK Fax: +44 (0) 1480 477833 +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

February 15, 2023 04:00 AM Eastern Standard Time

Image

Introducing MicroGuard™ by Microban®: antimicrobial technology for PU, EVA and PVC products

Microban International

Microban International is pleased to expand its portfolio of antimicrobial technologies with the introduction of MicroGuard ™, a series of antifungal additives for PVC, PU, and EVA applications including foam. MicroGuard technology provides high antifungal efficacy and 24/7 built-in protection, preventing microbial degradation to extend the useful product lifetime. This innovative solution from the global leader in antimicrobials is part of Microban’s commitment to bringing novel technologies to market with more friendly toxicity profiles than currently available agents. MicroGuard has been developed as a non-leaching antifungal agent comprised of active ingredients that are free from metals, offering an alternative to arsenic-based OBPA – a common antifungal additive – that is causing regulatory concerns due to its ability to contaminate water sources and harm aquatic life. Michael Ruby, President at Microban International, commented: “We are pleased to introduce MicroGuard, a metal-free technology designed to combat fungal growth on PVC products, as well as on PU and EVA foams. MicroGuard’s more favourable toxicity profile is ahead of the curve in terms of shifts in the regulatory landscape concerning built-in antifungals for these goods, offering manufacturers a highly effective built-in solution to increase product durability.” MicroGuard can be seamlessly integrated into PVC, PU and EVA products at the point of manufacture, and has been designed for use in a broad range of applications. The technology can be incorporated into outdoor PVC products – roofing membranes, tarpaulin, awnings and decking – and used to treat goods manufactured from PU and EVA foams, including shoe soles, furniture cushions and mattresses. Dr Souvik Nandi, Vice President of Technology and Innovations at Microban International, added: “MicroGuard has been carefully developed using our extensive in-house expertise to meet the diverse needs of PU, EVA and PVC manufacturers. Available in both pellet and liquid formulations, MicroGuard has global registration to offer manufacturers confidence in treating their polymer products.” The technology is available to brands and manufacturers globally, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/microguard and get in touch with a representative today! Microban will be exhibiting MicroGuard at the AMI’s fifth PVC Formulation from February 21-22, 2023, where Mai Ha, Senior Product Development Engineer at Microban International, will be discussing how the next generation of PVC antimicrobials is creating a cleaner future. Microban will also be showcasing MicroGuard at booth 8725 in exhibit halls A-E at the International Roofing Expo (IRE) March 7 - 9, 2023. About Microban International Part of Barr Brands International (BBI), Microban International is home to the most trusted and well-known global brands in the antimicrobial, odour control, and sanitisation / disinfection markets – Microban® and Ultra-Fresh®. Our organisation has experienced over 100 collective years of growth and has revolutionised the industry. As the global leader, our proactive systems keep products cleaner, and control odours better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products around the world. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina with operations in North America, Europe, and Asia Pacific. For more information, please visit www.microban.com. © 2023 kdm communications limited Contact Details Audrey Jestin at kdm communications limited, St Neots, UK Fax: +44 (0) 1480 477833 +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

February 15, 2023 12:00 AM Eastern Standard Time

Image

Stanford University and VinBrain – To design a state-of-the-art AI-enabled platform to advance medical diagnosis and treatments

Vingroup

HANOI, VIETNAM – Media OutReach – 14 February 2023 - On Jan 12 (PST Time), Mr. Steven Truong, CEO of VinBrain, attended the Data Use Agreement Signing Ceremony at the Stanford campus (Palo Alto, USA) organized by Stanford Center for Artificial Intelligence for Medical and Imaging (AIMI). This ceremony occurred with AIMI’s Director, Professor Curtis Langlotz along with other distinguished AIMI leaders, and the VinBrain leadership team. To design a state-of-the-art AI-enabled platform for more accurate diagnosis and treatments, a tremendous amount of geographically distributed data, medical images, and patient medical records are required for system training. The DUA grants Stanford University and VinBrain the collaborative power to improve efficiency in radiology reports and advance AI in healthcare by sharing relevant de-identified data for model training and testing, while tackling complexity, ambiguity, and limitations in medical image interpretation. Starting with 240,000 anonymized medical images and report pairs provided by Stanford through this DUA,VinBrain will work to improve the accuracy of the RadGraph method through a research collaboration with Stanford to extract clinical entities and relation annotations from a large dataset of full-text radiology reports. With this strong support from Stanford, VinBrain aims to raise the bar for research on AI solutions by collaborating beyond Vietnam to improve product quality, meanwhile, continuing to add and develop the most massive data source in Vietnam to date, with more than 2.3 million images being analyzed through the DrAid™ platform so far. Mr. Steven Truong affirmed: "VinBrain always strictly adheres to data security regulations according to USA standards." He also emphasized that Stanford sharing data with VinBrain demonstrates Stanford's absolute trust in VinBrain's commitment to data privacy and security. The DUA signed with Stanford University is not an overnight result but a long journey of 3+ years of collaboration. This collaboration has produced many research projects together that have achieved desirable clinical outcomes. Professor Curtis Langlotz, Director of the Center for Artificial Intelligence in Medicine and Stanford University also expressed his enthusiasms, “I remember the first time I met Steven at RSNA Spotlight organized by Stanford near San Francisco Airport. It was the beginning of this wonderful relationship that developed over time. We appreciate VinBrain’s leadership in research and the capabilities that they have. The speed of work is incredible, and I also appreciate the collaborative spirit of VinBrain.” He added, “I know that we've done a lot, but there's still a lot more to do. I look forward to continued collaborations. I'm glad we sat down together to sign this Agreement." This Agreement promises to comprehensively expand cooperation in the next areas of development, strengthen the relationship between VinBrain and the world’s leading University, and take VinBrain further in the research of AI-developed solutions for worldwide patients. About RadGraph: a novel method introduced by Prof. Pranav Rajpurkar (Harvard University) and Prof. Curtis Langlotz at Stanford. This collaboration works between Stanford University and VinBrain to address complexity, ambiguity, and limitations for interpreting medical images. About DrAid™: a platform of comprehensive artificial intelligence (AI) doctor assistant software developed by VinBrain to assist medical teams and doctors in diagnosing heart, lung, liver, and bone diseases based on digital medical images. The platform is evaluated to have superior efficiency compared to traditional methods in observing and analyzing medical images, helping in reducing overload and improving early detection in diagnosis. DrAid Radiology V1: An AI-enabled triage and notification software designed to aid the clinical assessment of adult Chest X-ray cases with features suggestive of pneumothorax. This software is FDA 510(K) cleared and apt for the US market. DrAid™ Appliance: an AI-enabled system to classify an adult Chest X-ray between normal and nearly 60 abnormal findings with higher-than-average quality standards of primary care physicians About VinBrain: VinBrain is a leading AI healthcare products company, funded by Vingroup, the largest conglomerate by market capitalization in Vietnam. Its mission is to infuse AI and IoT to improve people’s lives and productivity. Contact Details Media Contact v.chidqd1@vingroup.net Company Website https://vinbrain.net

February 14, 2023 10:30 AM Eastern Standard Time

Image

Acurx is Setting a High Bar for New Treatments in C. diff

Acurx Pharmaceuticals Inc

A New Gold Standard for C. diff Therapy Could be in the Offing; Next Data Release Expected in 2Q23 Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and recurrent infection. Primary C. diff is defined as the first episode of C. diff, while recurrent C. diff refers to the second or additional episodes following the primary infection. Re-infection occurs in up to 35% of individuals, with the risk of recurrence increasing with each episode. “Recurrence is the key cause of C. diff mortality and the principal contributor of C. diff’s more than two billion dollars in annual cost to the U.S. healthcare system,“ says David Luci, CEO of Acurx Pharmaceuticals ( Nasdaq; ACXP ), which is currently in Phase 2 clinical trials with a drug candidate that is showing high promise in curing C. diff infections in patients with primary C. diff or recurrent C. diff and, at the same time, preventing recurrence. In a Phase 2a study of the company’s C. diff candidate, called ibezapolstat, all ten patients enrolled were clinically cured of infection within two days of the end of treatment with no recurrence of C. diff at the 28-day follow-up visit. The positive clinical and safety results coupled with the beneficial effects on the gut microbiome resulted in the early termination of the study, and provided the first clinical hint of ibezapolstat’s potential superiority over vancomycin based on historical data. A 64-patient Phase 2b study is currently enrolling patients to further assess the efficacy and safety of ibezapolstat and its effects on the gut microbiome compared to vancomycin. The study will evaluate the comparative effects of ibezapolstat on clinical cure and sustained clinical cure (defined as clinical cure at the end of treatment visit and no recurrence within 28 days). It is expected that study enrollment will complete in 1Q 2023, with the release of interim results planned for 2Q 2023. Costly, Age Indifferent Infection with High Death Rate C. diff affects individuals of any age and is associated with significant and troublesome symptoms and mortality. Over the past decades, there has been a rapid increase in the incidence of community-acquired infection. C. diff has a profound economic impact on the healthcare system and patients due to recurrences, hospitalization, prolonged length of stay, and the cost of treatment which amount to roughly $2.8 billion dollars annually in the U.S—not to mention indirect societal costs such as loss of paid employment, and family disruptions. Vacnomycin has been the gold-standard antibiotic for treating C. diff and many other life-threatening infections since its introduction in 1965. “It’s a great drug. It has lasted roughly six decades as the go-to therapy for C. diff with very little competition”, notes Mr. Luci. “But its growing weakness, especially in preventing re-infection, has left a grizzly trail of serious sickness and a death rate of about 20,000 annually in the U.S. alone.” Clinical data collected over the years indicates that a typical new antibiotic has a peak efficacy of about five years and thereafter the process of antimicrobial resistance begins to set in —"a process by which bacteria learn to identify an antibiotic as a medicine and then find a way to morph their properties to avoid being killed by it,” explains Mr. Luci. “That’s why most antibiotics become less and less effective over time.” With today’s approved therapies, the estimated C. diff recurrence rate is around 20% after the initial treatment, increasing to 60% after multiple recurrences. Ibezapolstat - Gentle on Gut Flora Whilst Targeting Drug-Resistant Disease-Causing Bacteria The gut microbiome (also called gut flora) consists of trillions of microorganisms – such as bacteria and viruses – living inside the digestive tract. These microbes play an essential role in health, helping to break down food, absorb nutrients, and to protect against disease-causing microorganisms. Research has shown that changes in the composition and diversity of gut microbiomes can dramatically affect physical and mental well-being. A recently published Phase 1 study of Ibezapolstat in 10 healthy volunteers demonstrated that that Acrux’s C. diff candidate was effective against C. diff and caused changes in the structure and behavior of disease-causing bacteria, but not healthy bacteria. The results suggest that ibezapolstat is associated with a lower risk of C. diff recurrence than vancomycin. Furthermore, ibezapolstat did not adversely affect the gut microbiome, whilst vancomycin had undesirable effects on the gut microbiome and was ineffectual against drug-resistant bacteria. Current data would suggest that Ibezapolstat seems to be on a solid trajectory to become a first-line treatment for C. diff infection, given its ability to affect a total reduction in recurrence rates, would could lead to improvements in morbidity and mortality and a significant savings in healthcare and societal costs. This is in stark contrast to the failure of Pfizer ’s (NYSE: PFE) vaccine candidate PF-06425090 and the antibiotics cadazolid (investigated by Johnson & Johnson (NYSE: JNJ)) and surotomycin (investigated by Merck & Co (NYSE: MRK)) to meet their primary outcomes. More recently, in September 2022, Summit Therapeutics (Nasdaq: SMMT) decided to furlough development of ridinilazole for pediatric C. diff, and in January of this year, Finch Therapeutics Group (Nasdaq: FNCH) ended its development work on a fecal transplant technology for recurrent C. diff. Click here for more information about Acurx (ACXP) About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Featured Photo by Edward Jenner on Pexels Contact Details David P. Luci, President & CEO davidluci@acurxpharma.com

February 14, 2023 08:01 AM Eastern Standard Time

Image

Healthcare

With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO

How To Improve Mental Well-Being — TruBrain’s Non-Pharmaceutical Solutions Could Help Fight Anxiety For Stress-Free Living

Applied UV’s (NASDAQ: AUVI) Subsidiary Embarks On Research Partnership With Johnson Controls And Ushio America To Study The Efficacy And Safety Of Filtered Far UV-C Disinfection Technology

Introducing MicroGuard™ by Microban®: antimicrobial technology for PU, EVA and PVC products

6 Best Coursework Writing Services For Academic Excellence 📚

Introducing MicroGuard™ by Microban®: antimicrobial technology for PU, EVA and PVC products

Introducing MicroGuard™ by Microban®: antimicrobial technology for PU, EVA and PVC products

Stanford University and VinBrain – To design a state-of-the-art AI-enabled platform to advance medical diagnosis and treatments

Acurx is Setting a High Bar for New Treatments in C. diff